Thioridazine pharmacokinetic-pharmacodynamic parameters "Wobble" during treatment of tuberculosis: a theoretical basis for shorter-duration curative monotherapy with congeners.
about
Reduced emergence of isoniazid resistance with concurrent use of thioridazine against acute murine tuberculosis.Sterilizing activity of thioridazine in combination with the first-line regimen against acute murine tuberculosis.Amikacin Pharmacokinetics/Pharmacodynamics in a Novel Hollow-Fiber Mycobacterium abscessus Disease Model.Tigecycline Is Highly Efficacious against Mycobacterium abscessus Pulmonary DiseaseSusceptibility Testing of Antibiotics That Degrade Faster than the Doubling Time of Slow-Growing Mycobacteria: Ertapenem Sterilizing Effect versus Mycobacterium tuberculosis.Moxifloxacin's Limited Efficacy in the Hollow-Fiber Model of Mycobacterium abscessus Disease.Thioridazine as Chemotherapy for Mycobacterium avium Complex DiseasesLinezolid for Infants and Toddlers With Disseminated Tuberculosis: First Steps.High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial.Energy metabolism and drug efflux in Mycobacterium tuberculosisNonclinical models for antituberculosis drug development: a landscape analysis.Thioridazine: A Non-Antibiotic Drug Highly Effective, in Combination with First Line Anti-Tuberculosis Drugs, against Any Form of Antibiotic Resistance of Mycobacterium tuberculosis Due to Its Multi-Mechanisms of Action.Ceftazidime-avibactam has potent sterilizing activity against highly drug-resistant tuberculosis.Sterilizing Effect of Ertapenem-Clavulanate in a Hollow-Fiber Model of Tuberculosis and Implications on Clinical Dosing.Linezolid Dose That Maximizes Sterilizing Effect While Minimizing Toxicity and Resistance Emergence for Tuberculosis.Systematic Analysis of Hollow Fiber Model of Tuberculosis Experiments.
P2860
Q33798280-56435591-3F04-4DD9-B615-3AD9749CBC2EQ34057500-9AA3A9B5-50CB-45A6-9D1B-E92E32742437Q36644647-B70E288F-B9F6-4E2E-A512-824FACE6E0A5Q36887811-8F338697-7DE2-47FE-A366-6D828A34E5C9Q36888124-C5B8848D-18F8-4A36-8937-41C860D87678Q36933441-A9E2D5F0-55C0-4B87-A16B-66356AB1A3B2Q37120152-B04CDF23-7CA4-45FD-848B-CCEA916D3617Q37339287-A7CBD2D3-653C-4A8F-AE62-4CE15A470294Q37507802-20A9B42E-14ED-4582-AB86-904DA3235AB6Q37712986-7D3DC436-03C9-4EA0-8F6B-B4341A9344CAQ38502294-47A54D6D-50FB-436E-87CF-DCDFD4E839E3Q38872058-C16E2966-7157-4A0D-9174-223E96AA4979Q40065397-EC53CAAC-AD74-49D7-84A4-C65F5E008B4FQ40139991-9DEB5917-30C8-40FD-B1C7-8FB7B85B6FA6Q40184248-A3DE2A89-F074-44DD-87DD-42A2152831E2Q41082086-97BD95AA-F9F2-4ECD-8CBD-11A343743FD9
P2860
Thioridazine pharmacokinetic-pharmacodynamic parameters "Wobble" during treatment of tuberculosis: a theoretical basis for shorter-duration curative monotherapy with congeners.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 16 September 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Thioridazine pharmacokinetic-p ...... ve monotherapy with congeners.
@en
Thioridazine pharmacokinetic-p ...... ve monotherapy with congeners.
@nl
type
label
Thioridazine pharmacokinetic-p ...... ve monotherapy with congeners.
@en
Thioridazine pharmacokinetic-p ...... ve monotherapy with congeners.
@nl
prefLabel
Thioridazine pharmacokinetic-p ...... ve monotherapy with congeners.
@en
Thioridazine pharmacokinetic-p ...... ve monotherapy with congeners.
@nl
P2093
P2860
P356
P1476
Thioridazine pharmacokinetic-p ...... ve monotherapy with congeners.
@en
P2093
Chandima Wasana Siyambalapitiyage Dona
Claudia Meek
Jotam Pasipanodya
Richard Leff
Sandirai Musuka
P2860
P304
P356
10.1128/AAC.00829-13
P407
P577
2013-09-16T00:00:00Z